• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

Professional Introduction to Compound with CAS No. 1060817-08-4 and Product Name: 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine

1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine, identified by the Chemical Abstracts Service (CAS) number 1060817-08-4, is a significant compound in the realm of pharmaceutical chemistry and drug discovery. This molecule, featuring a complex indazole core structure, has garnered considerable attention due to its potential pharmacological properties and its role in the development of novel therapeutic agents. The indazole scaffold is particularly noteworthy, as it is a privileged structure in medicinal chemistry, often associated with bioactive molecules that interact with various biological targets.

The chemical structure of 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine encompasses a nitrogen-rich heterocyclic system, which is known to enhance binding affinity and selectivity in drug design. The presence of two methyl groups at the 1 and 5 positions of the indazole ring introduces steric and electronic modifications that can influence the compound's interactions with biological macromolecules. These structural features make it a promising candidate for further exploration in the context of enzyme inhibition, receptor binding, and other pharmacological applications.

In recent years, there has been a growing interest in indazole derivatives as potential therapeutic agents. The indazole core is found in several FDA-approved drugs, highlighting its importance in drug development. For instance, indazole-based compounds have shown promise in the treatment of neurological disorders, infectious diseases, and cancer. The structural versatility of indazoles allows for modifications that can fine-tune their pharmacokinetic and pharmacodynamic properties, making them valuable tools in medicinal chemistry.

1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine has been studied in the context of its potential role as an intermediate in the synthesis of more complex pharmaceutical molecules. The amine functional group at the C3 position of the indazole ring provides a reactive site for further chemical modifications, enabling the construction of diverse pharmacophores. This flexibility has made it a subject of interest for synthetic chemists aiming to develop novel drug candidates.

One of the most compelling aspects of this compound is its potential application in the development of targeted therapies. The indazole scaffold is known to interact with various biological targets, including enzymes and receptors involved in critical cellular pathways. For example, indazole derivatives have been investigated for their ability to modulate kinases and other enzymes implicated in cancer progression. The methylation at positions 1 and 5 may enhance metabolic stability while maintaining binding affinity to these targets.

The synthesis of 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, such as palladium-catalyzed cross-coupling reactions and transition-metal-mediated transformations, have been employed to construct the indazole core efficiently. These synthetic strategies are essential for producing sufficient quantities of the compound for preclinical studies and eventual clinical trials.

Recent advancements in computational chemistry have also played a crucial role in understanding the pharmacological properties of 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine. Molecular modeling techniques allow researchers to predict how this compound might interact with biological targets at the atomic level. This approach has been instrumental in guiding medicinal chemists toward designing more effective derivatives with improved pharmacokinetic profiles.

The potential therapeutic applications of 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine extend beyond oncology. There is growing evidence suggesting that indazole derivatives may have antimicrobial properties, making them candidates for treating resistant bacterial infections. Additionally, these compounds have shown promise in preclinical studies as modulators of inflammatory pathways, which could be beneficial in treating autoimmune diseases and chronic inflammatory conditions.

In conclusion, 1-(1,5-Dimethyl-1H-indazol-3-yl)methanamine (CAS No. 1060817-08-4) represents a fascinating compound with significant potential in pharmaceutical research. Its unique structural features and reported biological activities make it a valuable asset for drug discovery efforts aimed at addressing various diseases. As research continues to uncover new insights into its pharmacological properties, this molecule is likely to play an increasingly important role in the development of next-generation therapeutic agents.

• 440099-33-2((1-Methyl-1H-indazol-3-yl)methanamine hydrochloride)
• 1177329-20-2((5-Methyl-1H-indazol-3-yl)methanamine)
• 124491-38-9(methyl(1-methyl-1H-indazol-3-yl)methylamine)
• 1234616-62-6((2,3-dimethyl-2H-indazol-5-yl)methanamine)
• 1234616-52-4((2,3-dimethyl-2H-indazol-6-yl)methanamine)
• 128364-67-0(1H-Indazole,3-methyl-1-(phenylmethyl)-)
• 739359-10-5(1-Methyl-1H-indazole-3-methanamine)
• 34879-84-0(1,3-Dimethyl-1H-indazole)
• 1093860-45-7((1-Methyl-1H-indazol-3-yl)methylamine Dihydrochloride)
• 1015846-71-5(1,5-Dimethyl-1H-indazole-3-carbonitrile)